Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22279878 | 1.00 | PKM (0.46) | PKMMAPTRAB9ATSHRMEN1 | |
| SCHEMBL20875895 | 0.86 | NAAA (0.41) | TSHRCYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL22279740 | 0.86 | NAAA (0.41) | TSHRCYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL20875888 | 0.82 | CTRB1 (0.41) | TSHRNAAA | |
| SCHEMBL20875887 | 0.82 | CTRB1 (0.41) | TSHRNAAA | |
| SCHEMBL8295083 | 0.82 | CTRB1 (0.41) | TSHRNAAA | |
| SCHEMBL20875936 | 0.79 | CTRB1 (0.39) | NAAA | |
| SCHEMBL22279590 | 0.78 | MAPT (0.54) | PKMMAPTRAB9ATSHRMEN1 | |
| SCHEMBL22279791 | 0.78 | MAPT (0.54) | PKMMAPTRAB9ATSHRMEN1 | |
| SCHEMBL20875879 | 0.78 | MAPT (0.54) | PKMMAPTRAB9ATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180479-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-11-23 | — | — | US | disclosed |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180479-B2 | Antiviral compounds | PLA2G1B, PLA2G4A, PLA2G4C | PKM 3412/4885MAPT 4574/4885RAB9A 1423/4885 |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G4A, PLA2G4C | PKM 3412/4885MAPT 4574/4885RAB9A 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.